Menu Search
Equities

Recursion Pharmaceuticals Inc

RXRX:NSQ

Recursion Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.58
  • Today's Change-0.26 / -3.32%
  • Shares traded6.81m
  • 1 Year change+38.83%
  • Beta0.8955
Data delayed at least 15 minutes, as of Nov 12 2024 21:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Recursion Pharmaceuticals Inc had net income fall 36.99% from a loss of 239.48m to a larger loss of 328.07m despite a 11.88% increase in revenues from 39.84m to 44.58m. An increase in the selling, general and administrative costs as a percentage of sales from 240.07% to 300.58% was a component in the falling net income despite rising revenues.
Gross margin35.07%
Net profit margin-579.51%
Operating margin-604.70%
Return on assets-55.66%
Return on equity-78.49%
Return on investment-65.45%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Recursion Pharmaceuticals Inc fell by 157.69m. Cash Flow from Financing totalled 140.13m or 314.38% of revenues. In addition the company used 287.78m for operations while cash used for investing totalled 10.23m.
Cash flow per share-1.39
Price/Cash flow per share--
Book value per share1.83
Tangible book value per share1.53
More ▼

Balance sheet in USDView more

Recursion Pharmaceuticals Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.35
Quick ratio--
Total debt/total equity0.0548
Total debt/total capital0.0519
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.